Withdrawal Study to Demonstrate the Maintenance Effect in the Treatment of Non-24-Hour Sleep-Wake Disorder

计划入组 20 人 · 首次发布于 2011 年 9 月 8 日

Tasimelteon for the Treatment of Non-24-hour Sleep-Wake Disorder (N24HSWD) in Blind Individuals With no Light Perception

计划入组 200 人 · 首次发布于 2011 年 9 月 5 日

Efficacy and Safety of Tasimelteon Compared With Placebo in Totally Blind Subjects With Non-24-Hour Sleep-Wake Disorder

计划入组 136 人 · 首次发布于 2010 年 7 月 15 日

Tasimelteon(Hetlioz)

C₁₅H₁₉NO₂

ZN-113

Sleep disorders(Triastek)

Life 24 Limited

Clayton Sleep Institute

SLEEP CLINIC CHOFU

Japan

HETLIOZ Demonstrates Significant Sleep Improvement in Primary Insomnia Trial Published in PLOS One

Centessa Pharmaceuticals Initiates Phase 2 Trial of ORX750 for Sleep-Wake Disorders

Key Advances in Neuromuscular and Movement Disorder Treatments Highlighted in 2024